1. Home
  2. BNS vs SNY Comparison

BNS vs SNY Comparison

Compare BNS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank Nova Scotia Halifax Pfd 3

BNS

Bank Nova Scotia Halifax Pfd 3

SELL

Current Price

$96.40

Market Cap

111.5B

Sector

N/A

ML Signal

SELL

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$47.45

Market Cap

95.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNS
SNY
Founded
1832
1994
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.5B
95.7B
IPO Year
2025
2001

Fundamental Metrics

Financial Performance
Metric
BNS
SNY
Price
$96.40
$47.45
Analyst Decision
Hold
Buy
Analyst Count
14
11
Target Price
★ $92.07
$53.48
AVG Volume (30 Days)
973.8K
★ 4.1M
Earning Date
12-02-2026
10-30-2026
Dividend Yield
3.41%
★ 5.34%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.64
$3.80
Revenue Next Year
$5.07
$5.20
P/E Ratio
$18.76
★ $6.14
Revenue Growth
N/A
N/A
52 Week Low
$65.24
$39.07
52 Week High
$96.17
$52.68

Technical Indicators

Market Signals
Indicator
BNS
SNY
Relative Strength Index (RSI) 55.56 70.87
Support Level $86.06 $42.79
Resistance Level $95.35 $45.40
Average True Range (ATR) 1.29 0.73
MACD 0.23 0.61
Stochastic Oscillator 60.35 94.03

Price Performance

Historical Comparison
BNS
SNY

About BNS Bank Nova Scotia Halifax Pfd 3

Bank of Nova Scotia is a global financial-services provider with over CAD 1.5 trillion in assets as of the end of July 2026. It has four major business segments: Canadian banking, international banking, global wealth management, and global banking and markets. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Latin America.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: